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Abstract
Protein entrapment and high-performance affinity chromatog-
raphy were used with zonal elution to examine the changes in 
binding that occurred for site-specific probes and various sul-
fonylurea drugs with normal and glycated forms of human 
serum albumin (HSA). Samples of this protein in a soluble 
form were physically entrapped within porous silica particles 
by using glycogen-capped hydrazide-activated silica; these 
supports were then placed into 1.0 cm × 2.1 mm inner diam-
eter columns. Initial zonal elution studies were performed 
using (R)-warfarin and l-tryptophan as probes for Sudlow 
sites I and II (i.e., the major drug binding sites of HSA), giving 
quantitative measures of binding affinities in good agreement 
with literature values. It was also found for solutes with mul-
tisite binding to the same proteins, such as many sulfonylurea 
drugs, that this method could be used to estimate the global 
affinity of the solute for the entrapped protein. This entrap-
ment and zonal approach provided retention information with 
precisions of ±0.1–3.3% (± one standard deviation) and elution 
within 0.50–3.00 min for solutes with binding affinities of 1 × 
104–3 × 105 M−1. Each entrapped-protein column was used for 
many binding studies, which decreased the cost and amount 
of protein needed per injection (e.g., the equivalent of only 
125–145 pmol of immobilized HSA or glycated HSA per injec-
tion over 60 sample application cycles). This method can be 
adapted for use with other proteins and solutes and should be 
valuable in high-throughput screening or quantitative studies 
of drug–protein binding or related biointeractions.
Keywords: entrapment, high-performance affinity, chroma-
tography, human serum albumin, glycation, drug-protein 
binding
Introduction
Diabetes is currently the seventh leading cause of death 
in the USA. This disease is characterized by an elevated 
level of glucose in blood and exists in two main forms: 
type I (juvenile or insulin-dependent) diabetes and type 
II (non-insulin-dependent or adult onset diabetes) [1]. 
One side effect of this disease is the glycation, or non-
enzymatic addition, of reducing sugars such as glucose 
to amine groups on proteins [2–4]. One protein in blood 
that is affected by glycation is human serum albumin 
(HSA) [2–8]. HSA is not only the most abundant protein 
in human plasma, but it also serves as an important car-
rier protein for many drugs, fatty acids, and other sol-
utes [9–12]. This protein has two major binding sites for 
drugs, which are commonly referred to as Sudlow sites 
I and II [10–12]. It is known Sudlow sites I and II, or res-
idues near these sites, may be altered as a result of gly-
cation [2–8, 13–15]. It has also been determined that this 
process could potentially alter the binding of some sol-
utes with HSA [2–4, 16], including several sulfonylurea 
drugs used to treat type II diabetes [17–21].
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The purpose of this study is to examine a new combi-
nation of tools for quickly examining the overall binding 
of HSA to drugs and solutes and to determine how such 
binding might be affected by glycation. This approach 
is based on the use of entrapped proteins and high-per-
formance affinity chromatography (HPAC). HPAC is a 
separation method in which a biologically related bind-
ing agent is used as the stationary phase on a high-per-
formance liquid chromatography (HPLC) support such 
as porous silica [22–25]. This approach has been shown 
in many past reports to be a useful method for studying 
and characterizing the binding of solutes with biological 
agents [22, 26], including the interactions of drugs and 
other solutes with proteins such as HSA [23–25]. Advan-
tages of HPAC include its speed, precision, ease of auto-
mation, and ability to reuse the same protein prepara-
tion for many experiments [23, 25].
In most studies with HPAC, proteins and other bind-
ing agents are covalently immobilized onto the sur-
face of a support. However, this immobilization process 
can lead to a decrease or loss of activity for the binding 
agent owing to multisite attachment, improper orien-
tation, or steric effects [26, 27]. Recently, a noncovalent 
immobilization technique has been described for the 
physical entrapment of soluble proteins such as HSA 
within the pores or near the surface of silica supports 
[28]. This approach, as illustrated in Figure 1, makes 
use of large particles of mildly oxidized glycogen that 
combine with hydrazide-activated silica and entrap sol-
uble proteins on the support while still allowing access 
of small solutes and binding targets to these proteins. 
This method has been shown in prior work with fron-
tal analysis and a site-selective probe for Sudlow site I, 
i.e., (S)-warfarin, to produce immobilized normal HSA 
with essentially full activity and binding constants that 
are in good agreement with values that are seen for sol-
uble HSA [28].
This study will examine the combined use of HPAC 
columns and protein entrapment to compare the overall 
binding of representative drugs and probe compounds 
with normal HSA and glycated HSA. The emphasis will 
be on the use of such columns in zonal elution studies 
[23–25] to provide a relatively fast means for examining 
the binding of the entrapped proteins to injected targets. 
This method will first be evaluated by using it to com-
pare the binding of normal HSA versus glycated HSA to 
(R)-warfarin and l-tryptophan (i.e., site-selective probes 
for Sudlow sites I and II, respectively) [10, 29, 30]. This 
approach will then be extended to studies examin-
ing the overall binding of several sulfonylurea drugs 
to the same protein samples. These results will be com-
pared with those obtained by other methods for simi-
lar systems and should provide valuable data regarding 
the use of protein entrapment and HPAC for compar-
ing the binding properties of normal and modified pro-
teins. The same data should help illustrate the potential 
for this combined approach in high-throughput screen-
ing of drug–protein interactions.
Experimental
Chemicals
p-Periodic acid (periodic acid reagent, or H5IO6), gly-
cogen (from bovine liver), HSA (Cohn fraction V, 99% 
globulin free, 99% fatty acid free), glycated HSA (95% 
lyophilized, lot no. 115K6108, prepared in vitro and con-
Figure 1. Entrapment of 
a protein by reaction of 
hydrazide-activated silica 
with mildly oxidized 
glycogen. Details on this 
approach are provided in 
the text.
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taining 1.8 mol hexose per mole of HSA), (R)-warfa-
rin, l-tryptophan, acetohexamide, gliclazide, and tolbu-
tamide were purchased from Sigma-Aldrich (St. Louis, 
MO, USA). Nucleosil Si-300 silica (300-Å pore size, 7-μm 
particle diameter) was purchased from Macherey-Nagel 
(Düren, Germany). Reagents for the micro bicinchoninic 
acid (BCA) protein assay were from Pierce (Rockford, IL, 
USA). Other chemicals were of the purest grades avail-
able. Econo-Pac 10 DG disposable 10-mL desalting col-
umns were obtained from Bio-Rad Laboratories (Hercu-
les, CA, USA). All solutions were prepared using water 
from a NANOpure purification system (Barnstead, 
Dubuque, IA, USA) and filtered through 0.20-μm GNWP 
nylon membranes from Millipore (Billerica, MA, USA).
Instrumentation
The chromatographic system consisted of a JASCO 
(Tokyo, Japan) PU-980i intelligent HPLC isocratic 
pump, a Rheodyne (Cotati, CA, USA) Advantage PF 
ten-port valve, and a JASCO UV-975 UV/vis detector. 
The detection wavelengths were as follows: 304 nm, (R)-
warfarin; 280 nm, l-tryptophan; 205 nm, sodium nitrate; 
248 nm, acetohexamide; 226 nm, gliclazide; and 250 nm, 
tolbutamide. Data were collected using an interface and 
software from National Instruments (Austin, TX, USA). 
The temperature of the columns and mobile phases was 
controlled using a PolyScience (Buffalo Grove, IL, USA) 
circulating water bath and a water jacket from Alltech 
(Deerfield, IL, USA). All columns were packed using 
an HPLC column slurry packer from Alltech. The chro-
matographic data were analyzed using Peakfit 4.12 (Jan-
del Scientific Software, San Rafael, CA, USA).
Methods
The overall scheme used for protein entrapment was 
based on a procedure reported in [28] using normal 
HSA as a model; the same method was found to entrap 
glycated HSA in preliminary studies in this prior report. 
The oxidation of glycogen was performed in pH 5.0 
buffer containing 20 mM sodium acetate and 15 mM 
sodium chloride. A 4.0 mL solution was prepared by 
dissolving 135 mg of periodic acid and 17 mg of gly-
cogen in this buffer. The resulting solution was cov-
ered in aluminum foil, because of the light sensitivity 
of periodic acid, and was shaken at room temperature 
for 12–24 h. After oxidation, the glycogen was separated 
from the remaining periodic acid by using an Econo-Pac 
10DG disposable desalting column and pH 5.0, 0.10 M 
potassium phosphate buffer as the mobile phase. The 
resulting solution of oxidized glycogen had a concen-
tration of approximately 4.2 mg/mL, a final volume of 
around 4.0 mL, and approximately 0.5% oxidation of the 
glucose units in glycogen [28]. This solution was stored 
in pH 5.0, 0.10 M phosphate buffer at 4 °C.
The normal HSA and glycated HSA supports were 
prepared under the same immobilization conditions. 
A 50 mg/mL stock solution of each protein was first 
prepared in pH 5.0, 0.10 M potassium phosphate buf-
fer. The starting support, Nucleosil Si-300, was con-
verted into a hydrazide-activated form according to a 
previous procedure [31]. To create the entrapped-pro-
tein support, 80 mg of hydrazide-activated silica was 
combined with 160 μL of the protein solution. This 
mixture was sonicated under a vacuum for 15 min to 
remove any air trapped within the support’s pores. A 
380-μL portion of the oxidized glycogen solution was 
then added, and this mixture was shaken at room tem-
perature for 12 h. During the final hour of the reaction, 
200 μL of a 2 mg/mL oxalic dihydrazide solution in 
pH 5.0, 0.10 M phosphate buffer was added to the reac-
tion mixture to combine with any remaining aldehyde 
groups on the glycogen. After immobilization, the sup-
port was washed several times with pH 7.4, 0.067 M 
potassium phosphate buffer. A control support was 
prepared in the same manner by using only pH 5.0, 
0.10 M phosphate buffer in place of the protein solu-
tion during the entrapment step [28]. The protein con-
tent of each final support was determined in triplicate 
by using a micro BCA assay, with soluble HSA or gly-
cated HSA being used as the standard and the control 
support being used as a blank.
All supports were downward slurry-packed into sep-
arate 1.0 cm × 2.1 mm diameter stainless steel columns 
at 27.6 MPa (4,000 psi) using pH 7.4, 0.067 M potassium 
phosphate buffer as the packing solution. The columns 
were stored at 4 °C in this packing solution. The sam-
ple solutions for the chromatographic studies were pre-
pared in pH 7.4, 0.067 M potassium phosphate buffer, 
which was also used as the mobile phase. Stock solu-
tions with a concentration of 30 μM (R)-warfarin, or 
100 μM l-tryptophan, acetohexamide, gliclazide, or tol-
butamide were prepared in the same pH 7.4 buffer and 
diluted with this pH 7.4 buffer to give 10 μM working 
samples for these analytes; these sample concentrations 
were found to be sufficiently low compared with the col-
umn’s overall binding capacity to provide linear elution 
conditions during the retention factor measurements.
A 20-μL volume of each 10 μM sample solution was 
injected in triplicate onto the entrapped-protein col-
umns and the control column at 37 °C. Flow rates of 0.1-
1.0 mL/min were used to examine the binding of each 
analyte to the columns. The void time of each column 
was determined by making triplicate 20-μL injections of 
25 μM sodium nitrate in the presence of pH 7.4, 0.067 M 
potassium phosphate buffer at all the flow rates tested. 
Sodium nitrate has routinely been used in the past as 
a void volume marker for columns containing cova-
lently immobilized HSA and glycated HSA, as well as 
with columns containing hydrazide-activated silica, 
and has been found to give good agreement with calcu-
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lated void volumes based on the known packing den-
sities and porosities of the corresponding supports [19–
21, 23, 25, 28–31]. The void time of the system was deter-
mined by repeating the injections of sodium nitrate but 
using a zero-volume union in place of the column. A fit 
to an exponentially modified Gaussian curve was used 
to determine the central moment of each peak for the 
calculation of retention factors.
Results and discussion
General properties of entrapped HSA and glycated 
HSA columns
The entrapment supports were found through a BCA 
protein assay to contain 37 (± 1) mg HSA per gram of 
silica, or 32 (± 2) mg glycated HSA per gram of silica, 
where the values listed in parentheses throughout this 
article represent a range of ± one standard deviation. 
These supports were packed into 1.0 cm × 2.1 mm inner 
diameter columns, resulting in a total protein content in 
terms of moles (m Ltotal) of 8.7 nmol or 7.5 nmol (i.e., 500 
μg or 580 μg) for the HSA and glycated HSA (note these 
values were estimated by using a packing density of 
0.45 g/cm3 for the support material, as reported by the 
manufacturer, and a molar mass for HSA and glycated 
HSA of 66.5 kDa). The columns were found to be stable 
and give reproducible retention factors over the course 
of more than 60 sample injection cycles and approxi-
mately 4 months of operation. Because each entrapped 
protein sample was used for many binding studies, this 
resulted in a decrease in the cost and overall amount of 
protein needed per injection. For instance, the equiv-
alent of only 125-145 pmol (8.3-9.7 μg) of immobilized 
HSA or glycated HSA was used per injection when 
employed over the course of 60 application cycles.
These columns were initially evaluated by using 
zonal elution as a rapid means for obtaining estimates 
of binding affinities for injected probe compounds or 
solutes with the entrapped proteins. Figure 2 provides 
some typical chromatograms that were obtained for 
(R)-warfarin and l-tryptophan on these columns. When 
compared with the control column containing no pro-
tein, both the normal HSA column and the glycated 
HSA column showed markedly increased retention 
for both probe compounds. (R)-warfarin, which has an 
association equilibrium constant of roughly 2 × 105–3 × 
105 M-1 for normal HSA [29], was eluted within 5-6 min 
at 0.5 mL/min from both types of entrapped-protein col-
umns and within 2.5-3 min from the same columns at 1.0 
mL/min. l-tryptophan, which has a tenfold lower asso-
ciation equilibrium constant of approximately 1 × 104–2 
× 104 M-1 for normal HSA [30], was eluted in only 1.0-1.5 
min at 0.5 mL/min from both types of entrapped-pro-



































Reproducible retention factors and stable binding char-
acteristics were obtained on these columns for tripli-
cate injections obtained over five flow rates ranging 
from 0.1 to 1.0 mL/min, with retention factors showing 
only random variations of ±4% overall for (R)-warfarin 
and ±11% for l-tryptophan. The precisions of the reten-
tion factors measured at individual flow rates for the 
same solutes ranged from ±0.4 to ±1.1% and from ±0.6 
to ±3.3%, respectively, with the precision increasing as 
slower flow rates and longer residence times were used.
Binding of (R)-warfarin with entrapped HSA and 
glycated HSA
The next part of this study used HPAC and the columns 
containing entrapped samples of normal HSA or gly-
cated HSA to evaluate the binding of these columns to 
(R)-warfarin as a probe for Sudlow site I (i.e., the war-
farin–azapropazone site) [10, 29, 32]. This drug (see Fig-
ure S1 for the structure) has been previously shown to 
bind to both normal and glycated HSA in a site-selective 
manner. The association equilibrium constants at pH 7.4 
Figure 2. Chromatograms obtained for the injection of a (R)-
warfarin or b l-tryptophan as a site-selective probe onto a con-
trol column containing no entrapped protein or columns con-
taining entrapped normal human serum albumin (HSA) or 
glycated HSA. These results were obtained at 0.50 mL/min. 
Other conditions are given in the text.
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and 37 °C for these interactions have been estimated by 
various methods for normal HSA [2, 29, 30, 32–34] and 
by frontal analysis for in vitro glycated HSA [2], thus 
providing reference values for this current study for the 
evaluation of the entrapped-protein columns.
In the zonal elution approach that was used in this 
study, the specific retention factor (k) was determined 
for an injected drug or solute on a given protein column 
after correcting for the effect of any nonspecific interac-
tions with the support on the total retention, e.g., a cor-
rection for (R)-warfarin which was only 2.5-2.6% of the 
total retention seen on the entrapped protein columns; 
this approach was adequate for the current study, but 
a more thorough analysis of the nonspecific interactions 
could be obtained in future work through frontal anal-
ysis. The use of the specific retention factor provided a 
relatively fast and easy way of measuring and compar-
ing the level of binding for each injected solute on the 
entrapped-protein columns. For more detailed studies 
of binding, the resulting value of k due to the entrapped 
protein could also be directly related to the global affin-
ity constant (nKa′) of the solute with the immobilized 
protein, as represented by the general expression in 
Equation 1 for any group of independent binding sites 
[23, 25]:
Single-site or multisite binding:  k = 
(nK′a mLtotal )    (1)
                                                                             VM  
where mLtotal again represents the total number of moles 
of protein, and VM is the column void volume [23].
It is important to note in Equation 1 that nKa′ is a 
number-weighted sum of the association equilibrium 
constants for all binding sites of the solute on the immo-
bilized protein, as indicated by Equation 2 for a system 
with multiple, independent binding sites [23, 25]:
nKa’ = ∑ (ni Kai )                              (2)
In Equation 2, ni  represents the relative number of 
moles of binding site i for a given solute per mole of 
protein, and Kai  is the association equilibrium constant 
for the same site and solute. If only a single type of bind-
ing site for a drug or solute is present and essentially all 
of the immobilized protein is present in an active form 
(i.e., as could occur for an entrapped but noncovalently 
immobilized protein), Equation 1 can be rewritten as 
Equation 3:
Single-site binding:    k  = 
(KamLtotal )                 (3)
                                                                   VM
In this specific case, n = 1 and nKa’ is now given by Ka, 
the association equilibrium constant for the solute at its 
binding site on the protein.
Table 1 summarizes the specific retention factors that 
were measured for (R)-warfarin on the columns con-
taining entrapped normal HSA and glycated HSA. To 
correct for differences in the protein content of these 
supports and to allow a direct comparison of their 
retention values, the specific retention factors were nor-
malized by dividing them by each support’s total pro-
tein content [35, 36]. When these normalized retention 
Table 1. Retention factors and global affinity constants measured for (R)-warfarin and l-tryptophan on columns containing 
entrapped normal human serum albumin (HSA) or glycated HSA
Type of HSA  Specific retention Normalized retention factor, Global affinity, 
and solute  factor, k a   k/(protein content) b   nKa′ (M-1) c 
Normal HSA
    (R)-warfarin 84.7 (± 0.5) 2.29 (± 0.06) 2.9 (± 0.1) × 105 
    l-tryptophan 5.7 (± 0.2) 0.15 (± 0.01) 1.8 (± 0.1) × 104 
Glycated HSA
    (R)-warfarin 78.5 (± 0.8) 2.45 (± 0.08) 3.1 (± 0.1) × 105 
    l-tryptophan 14.22 (± 0.03) 0.44 (± 0.01) 5.5 (± 0.2) × 104 
The values in parentheses represent a range of  ± one standard deviation, as based on triplicate measurements made over five flow 
rates (n = 15). As indicated in the text, the same range of flow rates was used to initially evaluate the reproducibility and stability 
of these columns over a range of operating conditions but gave no significant differences in the measured retention factors.
a. The specific retention factor was obtained by taking the difference between the overall retention factor on an entrapped-protein 
column and the retention factor due to nonspecific interactions measured for the same solute on the control column, with the 
latter value being 2.13 (± 0.05) for (R)-warfarin and 0.77 (± 0.03) for l-tryptophan.
b. The normalized retention factors were calculated by dividing the specific retention factors by the measured total protein content 
for each given support, using values of 37 (± 1) mg HSA per gram or 32 (± 2) mg glycated HSA per gram.
c. The value of nKa′ was estimated by using Equation 1 along with the specific retention factor (k) for each solute, the measured void 
volume (V M), and the number of moles of protein in the column (m Ltotal). The value used for VM was 29 μL and m Ltotal was 8.7 
nmol or 7.5 nmol for the normal HSA or glycated HSA columns, respectively; details on the determination of VM and m Ltotal are 
provided in the text.
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factors were compared, no significant difference at the 
95% confidence level (i.e., the confidence level used for 
all comparisons in this study) was seen in the values for 
(R)-warfarin on the columns containing normal HSA 
and glycated HSA. These results indicated the level of 
glycation present in this case did not have an observ-
able effect on the binding of (R)-warfarin with HSA at 
Sudlow site I. These results are consistent with previ-
ous data and conclusions obtained when frontal anal-
ysis was used to compare covalently immobilized nor-
mal HSA with in vitro glycated HSA that had levels of 
modification for the glycated HSA that were similar or 
equivalent to those used in the current study [2].
Using the fact that (R)-warfarin has only one major 
binding site on normal HSA and glycated HSA, and 
that most of these entrapped proteins should have 
been active, we used the retention data to further esti-
mate and compare the association equilibrium con-
stants for this interaction. These results are also pro-
vided in Table 1. The K a of 2.9 (± 0.1) × 10
5 that was 
calculated from the zonal elution data for (R)-warfarin 
with normal HSA was in good agreement with previ-
ously reported values of 2.1× 105–3.3 × 105 M-1 for this 
interaction under the same temperature conditions [2, 
29, 30, 32–34]. The K a of 3.1 (± 0.1) × 10
5 M-1 obtained for 
(R)-warfarin with the glycated HSA was also consistent 
with prior estimates of 2.3 (± 0.3) × 105–to 2.7 (± 0.3) × 
105 M-1 that have been made by frontal analysis for sim-
ilar preparations of this protein [2]. In addition, the cal-
culated K a values did not show any significant differ-
ence between the normal HSA and glycated HSA col-
umns, as noted in the prior studies [2].
Binding of l-tryptophan with entrapped HSA and gly-
cated HSA
The same columns as described in the previous section 
were examined for their binding to l-tryptophan as a 
probe for Sudlow site II (i.e., the indole–benzodiazepine 
site) [10, 30, 37]. Like (R)-warfarin, this solute (see Fig-
ure S1 for the structure) is known to bind to both nor-
mal and glycated HSA in a site-selective manner [2, 10, 
30]. The association equilibrium constant for the bind-
ing of l-tryptophan with normal HSA has also been 
determined by various techniques at 37 °C [30, 34, 37, 
38], and the binding of this solute under the same con-
ditions with in vitro glycated HSA has been previously 
examined by frontal analysis [2], again providing values 
that could be used to evaluate the performance of the 
entrapped-protein columns.
The results from the zonal elution studies that were 
obtained for l-tryptophan are included in Table 1. 
Unlike the data acquired for (R)-warfarin, the normal-
ized retention factors that were calculated for l-trypto-
phan showed a large change when going from normal 
HSA to glycated HSA, even after a correction had been 
made for differences in the total protein content of the 
columns. The normalized retention factor for l-tryp-
tophan on the entrapped glycated HSA column was 
roughly three times higher than that for l-tryptophan 
on the column containing normal HSA. This difference 
was significant at the 95% confidence level. The value of 
nK a′ between these two columns increased by the same 
factor and was again significant at the 95% confidence 
level. These results clearly indicated that the glycation 
of HSA did affect the binding of l-tryptophan to Sudlow 
site II, as was concluded in a previous study [2].
Given the fact that l-tryptophan has only one major 
binding site on HSA, the global affinity measured for this 
solute was assumed to represent the association equilib-
rium constant for this interaction. The average K a of 1.8 
(± 0.1) × 104 M-1 that was estimated by this approach for 
l-tryptophan with the entrapped normal HSA was in 
good agreement with previous values of 1.1 × 104–2.4 
× 104 M-1 that have been determined by other methods 
for this interaction at 37 °C [2, 30, 34, 37–39]. The K a of 
5.5 (± 0.2) × 104 M-1 measured for l-tryptophan with the 
entrapped glycated HSA also fit within the range of 5.2 
× 104–6.4 × 104 M-1 that has previously been measured 
by frontal analysis at 37 °C with in vitro glycated HSA 
preparations having similar levels of modification [2].
Binding of sulfonylurea drugs to entrapped HSA and 
glycated HSA
The final stage of this work used the entrapped HSA 
and glycated HSA columns to screen and compare the 
binding of various sulfonylurea drugs to these proteins. 
The sulfonylurea drugs considered in this study were 
acetohexamide, gliclazide, and tolbutamide (see the 
structures in Figure 3). Unlike (R)-warfarin and l-tryp-
tophan, these sulfonylurea drugs are known to bind to 
both Sudlow site I and Sudlow site II of normal HSA 
and glycated HSA, as well having a set of weaker inter-
action sites with these proteins [2, 17, 19–21]. Thus, for 
these drugs the use of retention factors to describe pro-
tein interactions would be expected to reflect the con-
tributions of multiple binding regions, as indicated by 
Equations 1 and 2, rather than a single binding site, as 
described by Equation 3.
Some typical chromatograms obtained in these stud-
ies are shown in Figure 4. As noted earlier with (R)-war-
farin and l-tryptophan, each of the sulfonylurea drugs 
exhibited a large difference in retention between the 
entrapped-protein columns and the control column. 
These drugs were eluted within 1.1-5.0 min at 0.5 mL/
min and within 0.6-2.5 min at 1.0 mL/min from the col-
umns containing the entrapped proteins. The measured 
retention factors had good reproducibility over flow 
rates ranging from at least 0.1 to 1.0 mL/min, with values 
varying by only ±3%, ±6%, or ±8% for acetohexamide, 
gliclazide, and tolbutamide, respectively. The retention 
factors measured at individual flow rates for the same 
drugs ranged from ±0.1 to ±0.6%, from ±0.1 to ±1.7%, 












and from ±0.2 to ±0.7%, respectively, and tended to 
improve as the flow rate was decreased and the resi-
dence time was increased.
Table 2 provides the specific retention factors that 
were measured for each of the sulfonylurea drugs on 
the normal HSA and glycated HSA columns. Normal-
ized retention factors that corrected for differences in 
the protein content of these columns were also calcu-
lated (see the footnote in Table 2). These sulfonylurea 
drugs showed an increase of 55-77% in the normalized 
retention factors for the glycated HSA column com-
pared with the normal HSA column. This increase in 
the normalized retention factor was in agreement with 
previously reported trends noted for these sulfonyl-
ureas when covalently immobilized samples of normal 
HSA and a preparation of in vitro glycated HSA similar 
to that used in the current study were used [18]. These 
trends also agreed with those seen in separate ultrafil-
tration studies using physiological levels of normal HSA 
and in vitro glycated HSA [20, 21, 40].
These retention data were further used to estimate 
the global affinities of each sulfonylurea drug with the 
entrapped samples of HSA and glycated HSA, as given in 
Table 2. In this case, it was known from prior studies that 
all of these drugs had two sets of binding sites on HSA 
(i.e., moderate-to-high affinity sites and weak binding 
regions), with most of this binding being attributed to one 
or two moderate-to-high affinity sites [17, 19–21]. Thus, 
the global affinities shown in Table 2 would be predicted 
from Equation 2 to represent a number-weighted sum of 
the association equilibrium constants for these sites; note 
that zonal elution competition studies with probes such 
as (R)-warfarin and l-tryptophan could also be employed 
to obtain information on the affinities at specific binding 
sites [17, 19–21, 23]. The relative trends shown in Table 2 
for these results were the same as noted for the normal-
ized retention factors, as would be expected from Equa-
tion 1 because these two sets of values were directly pro-
portional to each other.
The global affinities given in Table 2 compared well 
with those predicted by Eqs. 1 and 2 when calculating 
such results using previous binding capacities and asso-
ciation equilibrium constants obtained by frontal anal-
ysis, or a combination of these results with site-selec-
tive binding constants that were obtained by zonal elu-
tion at the higher-affinity sites for sulfonylurea drugs 
with covalently immobilized samples of normal HSA 
and in vitro glycated HSA [17, 19–21]. In each case, most 
of the calculated global affinity (i.e., 92-99% for aceto-
hexamide, 82-92% for gliclazide, and 92-98% for tolbu-
tamide) was due to the contributions of the moderate-
to-high binding regions for these drugs with HSA (i.e., 
Sudlow sites I and II).
Because the zonal elution approach used in this study 
employed direct measurements of retention to esti-
mate global affinities, the precision of this approach was 
much better than when combining association equilib-
rium constants and binding capacity results to calcu-
late global affinities. For instance, the global affinities 
obtained by using data from prior frontal analysis and 
zonal elution studies [17, 19–21] had typical final preci-
Figure 3. Basic structure of a sulfonylurea drug and the struc-
tures of the specific sulfonylurea drugs that were examined in 
this study.
Figure 4. Chromatograms obtained for acetohexamide on a 
control column containing no entrapped protein or on col-
umns containing entrapped normal HSA or glycated HSA. 
These results were obtained at 0.50 mL/min. Other conditions 
are given in the text.
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sions of ±20-50%, as based on error propagation. In con-
trast, the global affinities in Table 2 that were measured 
directly by zonal elution for the entrapped-protein col-
umns had precisions of ±3-10%.
Another potential advantage of using entrapped pro-
teins to measure global affinities was that little or no loss 
of activity should have occurred during the immobiliza-
tion process [26, 28]. This feature is essential if zonal elu-
tion data are to be used directly for determining binding 
constants [23, 25] and has made this approach generally 
impractical for use with covalent immobilization tech-
niques because the loss of protein activity is common 
during such coupling methods [23, 25, 26]. For instance, 
it was estimated from previous frontal analysis data [17, 
19–21] that a combined loss in activity of 35-60% for ace-
tohexamide, 45-59% for tolbutamide, and 75-80% for 
gliclazide occurred at Sudlow sites I and II when nor-
mal HSA and glycated HSA that had been covalently 
immobilized by the Schiff base method were used [17, 
19–21]. On the basis of prior work with (R)-warfarin and 
l-tryptophan, it is expected that a similar or even larger 
decrease in the activity for HSA might occur when other 
covalent immobilization methods are used [35, 36].
Concluding remarks
This report examined the use of entrapment and 
HPAC-based zonal elution studies to examine the 
changes in binding and overall affinity that occurred 
for site-specific probes and various sulfonylurea drugs 
with normal HSA versus glycated HSA. The columns 
created by entrapment gave retention factors with pre-
cisions of ±0.1-3.3% over the course of more than 4 
months of operation. The compounds retained on the 
entrapped-protein columns had elution times of less 
than 2.5-3.0 min at 1.0 mL/min for solutes with affin-
ities as high as 2× 105–3 × 105 M-1, e.g., as represented 
by (R)-warfarin on the normal HSA and glycated HSA 
columns, and less than 0.50-0.75 min for solutes with 
affinities down to 1× 104 –2 × 104 M-1, e.g., as seen for 
l-tryptophan on the normal HSA column. The ability to 
use these columns over many experiments produced 
a system that required the equivalent of less than 125-
145 pmol of immobilized protein per injection over 
60 application cycles. All of these characteristics are 
attractive for using such an approach in biointeraction 
studies and in the high-throughput screening of drug–
protein binding.
The ability of this method to provide a rapid, quan-
titative measure of binding affinity was also examined. 
In the case of solutes having a single major binding site 
on HSA, this approach could be used to determine the 
association equilibrium constant for the injected solutes 
with the entrapped proteins. For instance, the binding 
constants determined by this approach for (R)-warfa-
rin at Sudlow site I and for l-tryptophan at Sudlow site 
II were in good agreement with results reported with 
other techniques for normal HSA or glycated HSA [2, 
29, 30, 32–34, 37–39]. For solutes with multisite binding, 
this method could be used to estimate the global affinity 
of the solute for the entrapped protein. This was illus-
trated by using this approach to examine and compare 
the global affinities of various sulfonylurea drugs with 
normal HSA and glycated HSA. The values obtained 
again showed good agreement with trends and results 
that were predicted by other techniques and with use of 
similar protein preparations [17–21, 40].
Table 2. Retention factors and global affinity constants measured for sulfonylurea drugs on columns containing entrapped 
normal HSA or glycated HSA
Type of HSA  Specific retention  Measured global affinity,  Estimated global  
and drug factor (k) nKa′ (M-1) a  affinity, nKa′ (M-1) b 
Normal HSA
    Acetohexamide 46.5 (± 0.1) 1.6 (± 0.1) × 105  1.6 × 105–1.7 × 105 
    Gliclazide 17.1 (± 0.2) 5.8 (± 0.2) × 104  5.2 × 104–7.9 × 104 
    Tolbutamide 30.8 (± 0.1) 1.0 (± 0.1) × 105  1.0 × 105–1.1 × 105 
Glycated HSA 
    Acetohexamide 62.7 (± 0.1) 2.5 (± 0.1) × 105  1.6 × 105–1.8 × 105 
    Gliclazide 23.4 (± 0.1) 9.1 (± 0.3) × 104  6 × 104–12 × 104 
    Tolbutamide 47.0 (± 0.2) 1.9 (± 0.1) × 105  1.1 × 105–1.5 × 105 
The values in parentheses represent a range of ± one standard deviation, as based on triplicate measurements made over five 
flow rates (n = 15). The specific retention factors and values for nKa′ were determined in the same manner as described in 
Table 1. In obtaining the specific retention factors, we found the retention factor measured for nonspecific interactions by these 
drugs on the control column were 0.42 (± 0.04) for acetohexamide, 0.95 (± 0.10) for gliclazide, and 0.39 (± 0.04) for tolbutamide.
a. The nKa′ values measured for the normal HSA column were determined by using the following normalized retention factors: 
1.26 (± 0.03) for acetohexamide, 0.46 (± 0.01) for gliclazide, and 0.83 (± 0.02) tolbutamide. The nKa′ values for the glycated 
HSA column were found by using the following normalized retention factors: 1.96 (± 0.06) for acetohexamide, 0.73 (± 0.02) for 
gliclazide, and 1.47 (± 0.05) for tolbutamide.
b. These values were calculated by using frontal analysis and zonal elution data from [17, 19–21], as described in the text.
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These results indicate the entrapped-protein columns 
could be used directly with HPAC and zonal elution to 
estimate and compare binding constants or global affin-
ities for normal and modified proteins such as HSA and 
glycated HSA. Obtaining these quantitative estimates of 
affinities was made possible by the fact the entrapped 
protein was immobilized in a form that retained all or 
most of its original activity [28]. This feature, in turn, 
allowed the value of Ka or nKa′ to be determined from 
the measured retention factors of solutes if the pro-
tein content of the support was also known. This direct 
approach based on zonal elution was not possible in the 
past when covalent immobilization methods were used 
because of the loss of activity that occurs for some of the 
immobilized protein and the possible presence of dif-
ferent degrees of inactivation at separate regions on an 
immobilized protein [26]. Instead, retention measure-
ments have been used in the past to make only relative 
comparisons of activity [18, 23, 35, 36], or more compli-
cated and time-consuming methods based on frontal 
analysis or zonal elution plus competition experiments 
have been required to obtain binding constants that 
can be measured in a manner independent of the actual 
amount of active binding sites [2, 17, 19–21, 23–25].
The combined speed and ease of using zonal elu-
tion with the entrapped forms of proteins should make 
this approach attractive for clinical and pharmaceuti-
cal applications that may benefit from high-throughput 
screening or quantitative studies of binding between 
proteins and small soluble targets. For instance, the 
shifts in normalized retention factors and affinities that 
were measured when entrapped normal HSA and gly-
cated HSA were used are of potential interest in exam-
ination of how glycation may affect the protein bind-
ing of sulfonylurea drugs in blood [17–21]. Such infor-
mation, in turn, may help clinicians to avoid issues with 
using either too low or too high of a dose for these drugs 
when treating diabetes, which could lead to the unde-
sired side effects of inadequate glucose control or hypo-
glycemia, respectively [19, 41]. The same general meth-
ods as used in this study could be adapted for other pro-
teins and solutes or for comparing different protein pop-
ulations and biointeraction systems of interest in clini-
cal, pharmaceutical, or biomedical research.
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Figure S1.  Structures of R-warfarin and L-tryptophan
 
